6 citations
,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
8 citations
,
July 2003 in “Annals of the Rheumatic Diseases” A 13-year-old girl with various symptoms was successfully treated with an antibiotic called co-trimoxazole.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
6 citations
,
December 2023 in “Lancet. Infectious diseases/The Lancet. Infectious diseases” SIM01 significantly reduced post-COVID symptoms and is safe.
19 citations
,
April 2019 in “Veterinary dermatology” Oclacitinib effectively treated a skin condition in dogs that didn't respond to other immunosuppressants.
70 citations
,
October 2020 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.
55 citations
,
October 2020 in “Frontiers in Pharmacology” Targeting endolysosomes may help treat COVID-19.
21 citations
,
January 2021 in “Therapeutic Advances in Endocrinology and Metabolism” Testosterone may have a dual role in COVID-19, potentially worsening outcomes in men, and testosterone therapy could help some patients, but more research is needed.
December 2024 in “PubMed” Cyclosporine effectively treated a woman's stubborn skin condition.
20 citations
,
June 2003 in “Neurology” Tacrolimus and corticosteroids can improve symptoms of Satoyoshi syndrome.
8 citations
,
February 2022 in “Journal of Clinical Medicine Research” The MATH+ protocol aims to improve COVID-19 outcomes using a combination of specific treatments.
2 citations
,
April 2025 in “Biologics” Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
4 citations
,
October 2020 in “Research Square (Research Square)” Hydroxychloroquine, nitazoxanide, and ivermectin were similarly effective in treating early COVID-19.
100 citations
,
November 2021 in “Cell Research” Cepharanthine and Trifluoperazine are effective against SARS-CoV-2.
6 citations
,
March 2016 in “Scandinavian journal of immunology” Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
January 2002 in “대한피부과학회지” Cyclosporine combined with other treatments can help hair regrow in severe alopecia areata, but it may cause side effects.
6 citations
,
August 2020 in “Oncology nursing forum” Minocycline reduces acne rash, pyridoxine lowers hand-foot syndrome risk, and scalp cooling lessens hair loss from cancer treatments.
1 citations
,
May 2022 in “IntechOpen eBooks” Natural products might help treat COVID-19, but current drugs like hydroxychloroquine haven't worked.
17 citations
,
January 1993 in “Journal of Gastroenterology and Hepatology” Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.
April 2021 in “Journal of Investigative Dermatology” March 2025 in “European Journal of Medical Genetics” Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.
September 2025 in “Journal of the American Academy of Dermatology” Ritlecitinib may help treat alopecia areata by protecting hair follicles.
March 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” New treatments for severe alopecia areata, especially JAK inhibitors, are recommended as first-line therapy.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
37 citations
,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
9 citations
,
February 2023 in “Medicine” Traditional Chinese medicine may help relieve symptoms of Cronkhite-Canada syndrome.
March 2025 in “International Journal of Trichology” Janus kinase inhibitors may effectively treat resistant scalp conditions like folliculitis decalvans and dissecting cellulitis.
227 citations
,
April 2020 in “Cell” More precise, personalized therapies are needed for autoimmune diseases.